Key facts
- It has raised $5.2M across 3 recorded rounds; the latest was Seed Round ($1.0M) in Jul 2021.
- Notable investors include Sienna Investment Managers, National Cancer Institute.
- Ibex Biosciences has filed 4 Form Ds with the SEC since 2020, most recently Feb 2025 ($70K sold to 3 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Ibex Biosciences
Funding rounds
3 roundsAbout Ibex Biosciences
Developer of a research and development technology designed to discover, validate, and develop potential health systems. The company offers therapeutic antibodies, gene therapies, and regenerative medicine programs, enabling healthcare organizations to develop treatments that improve outcomes and potentially replace current standards of care.
- Sector
- Healthcare
- HQ
- MD
- Founded
- 2015
- Employees
- 11
- Website
- ibex.bio/
- Ownership
- Privately Held (backing)
Ibex Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Ibex Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Ibex Biosciences in its N-PORT filings yet. We sweep new filings monthly.